MAPK3 and hepatocellular carcinoma: Feng et al. showed that ERK1 and ERK2 are over-expressed in HepG2-ADM (adriamycin-resistant HepG2) cell line, indicating these two kinases as potential targets for treating multi-drug resistant HCC cells [42].